Sign in to view content

Phase IIIb TALON study of brolucizumab versus aflibercept in a matched treat-and-extend regimen to treat neovascular AMD: 32-week primary outcomes

Carl D. Regillo, MD

Video
Published 2022

Related

Cell Therapies for Atrophic AMD
Allen C Ho, MD FASRS
Updates from the Field
2020
Brolucizumab in HAWK/HARRIER: Outcomes, Efficacy, & Dosing Status – Everything You Need to Know!
David M. Brown, MD
Updates from the Field
2018
The Updated AREDS Simplified Severity Scale for Age-Related Macular Degeneration, Incorporating Reticular Pseudodrusen
Tiarnan D Keenan, BM BCh, PhD
Updates from the Field
2024

Category: AMD-Neovascular

See more